Cosmos Health Files Routine 8-K on Jan 18 Event
Ticker: COSM · Form: 8-K · Filed: Jan 22, 2024 · CIK: 1474167
Complexity: simple
Sentiment: neutral
Topics: current-report, routine-filing
TL;DR
**COSM filed a routine 8-K, nothing major to see here.**
AI Summary
Cosmos Health Inc. (COSM) filed an 8-K on January 22, 2024, reporting an event that occurred on January 18, 2024. This filing is a standard current report, indicating no major new financial events or changes in company structure, but rather a routine update. For investors, this means there's no immediate new information that would drastically alter the stock's valuation or outlook, suggesting business as usual for the company.
Why It Matters
This filing is a standard procedural update, indicating no significant new developments that would impact Cosmos Health Inc.'s stock price or business operations.
Risk Assessment
Risk Level: low — The filing is a standard current report with no specific disclosures of new risks or material changes.
Analyst Insight
A smart investor would note this as a routine filing and look for more substantive disclosures in future filings or earnings reports before making any investment decisions.
Key Numbers
- 001-41308 — SEC File Number (identifies Cosmos Health Inc.'s registration with the SEC)
- 24549083 — FILM NUMBER (internal SEC tracking number for the filing)
Key Players & Entities
- Cosmos Health Inc. (company) — the registrant filing the 8-K
- January 18, 2024 (date) — date of the earliest event reported
- January 22, 2024 (date) — date the 8-K was filed
- Nasdaq Capital Market (company) — exchange where Cosmos Health Inc.'s Common Stock is registered
- COSM (company) — trading symbol for Cosmos Health Inc.
FAQ
What is the purpose of this 8-K filing by Cosmos Health Inc.?
This 8-K filing is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating a report on an event that occurred on January 18, 2024. It appears to be a routine update without specific material disclosures mentioned in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 18, 2024.
On which stock exchange is Cosmos Health Inc.'s Common Stock traded?
Cosmos Health Inc.'s Common Stock, with a $.001 par value, is traded on the Nasdaq Capital Market under the trading symbol COSM.
What is the business address of Cosmos Health Inc. as stated in the filing?
The business address of Cosmos Health Inc. is 5 AGIOU GEORGIOU, PILEA, THESSALONIKI, Greece, with a Zip Code of 55438.
What is the telephone number for Cosmos Health Inc. provided in the filing?
The registrant's telephone number, including area code, is (312) 865-0026.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-22 16:19:38
Key Financial Figures
- $3.5 million — party for 3.2 million, or approximately $3.5 million at the exchange rate as of January 18,
- $400B — led "Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5
- $3.5M — 400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio" is at
Filing Documents
- cosm_8k.htm (8-K) — 24KB
- cosm_ex991.htm (EX-99.1) — 22KB
- cosm_ex991img1.jpg (GRAPHIC) — 6KB
- 0001477932-24-000313.txt ( ) — 180KB
- cosm-20240118.xsd (EX-101.SCH) — 6KB
- cosm-20240118_lab.xml (EX-101.LAB) — 14KB
- cosm-20240118_cal.xml (EX-101.CAL) — 1KB
- cosm-20240118_pre.xml (EX-101.PRE) — 9KB
- cosm-20240118_def.xml (EX-101.DEF) — 2KB
- cosm_8k_htm.xml (XML) — 3KB
01 OTHER EVENTS
ITEM 8.01 OTHER EVENTS On January 18, 2024, the Company announced it has successfully completed the acquisition of the licenses and rights of a comprehensive portfolio of 10 generic drugs from a related party for 3.2 million, or approximately $3.5 million at the exchange rate as of January 18, 2024. A press release announcing the matters described above and titled "Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio" is attached hereto as Exhibit 99.1 and incorporated herein by reference. Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
01 FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS (d) Exhibits Number 99.1 Press Release dated January 18, 2024 titled "Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. COSMOS HEALTH INC. Date: January 22, 2024 By: /s/ Georgios Terzis Georgios Terzis Chief Financial Officer 3